Aridis Pharmaceuticals  © 2009-2013 Le3 Web Designs

Site Map  |  Privacy Policy


|  Financial Conflict of Interest Policy

Aridis is focusing on anti-infective alternatives to conventional antibiotics.


May 15, 2013. Aridis Pharmaceuticals Announces the Acquisition of Monoclonal Antibody Products and Technologies from Kenta Biotech.  (More)

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

August 22nd, 2012. Manufacturing agreement with a commercial partner is completed, paving the way for GMP manufacturing of AerucinTM anti-Pseudomonas aeruginosa monoclonal antibody.

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

August 20th, 2012. Aridis completed a major research and development agreement with a multi-national partner to develop advanced vaccine formulation for a childhood vaccine

News


>> More News


“In hospitals, 190 million doses of antibiotics are administered each day.  133 million courses of antibiotics are prescribed by doctors each year”

American College of Physicians

www.acponline.org [02 February 2013]

Our anti-infective drug candidates offer

substantial improvement over conventional antibiotics in: